Clinical burden related to oral corticosteroid treatment of severe asthma in Spain: LEVANTE study.

Xavier Muñoz Gall Javier Dominguez-Ortega Silvia PascualCarlos Cabrera López Gustavo ReslerJavier NuevoGema Monteagudo

Published in: The Journal of asthma : official journal of the Association for the Care of Asthma (2022)

Results show a suboptimal control of severe asthma despite such high doses of OCS and persistence of disease burden regardless of the prescribing pattern in maintenance or bursts. There is therapeutic inertia to continue using OCS despite the increased risk of adverse effects and the availability of biologics.

Keyphrases

primary care
risk factors
emergency department
combination therapy
adverse drug
replacement therapy